Roche & reMYND enter into a strategic alliance to develop disease-modifying treatments for Parkinson’s and Alzheimer’s: http://tiny.cc/vgsr5
posted 9 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Op 27 oktober 2009 om 22.45u is in Merelbeke SMICSI geboren, het eerste Belgische proefbuisveulentje. read more
Bacteria possess an ingenious mechanism for preventing oxygen from harming the building blocks of the cell. This is the new finding of a team of biologists that includes Joris Messens of VIB, a life sciences research institute in Flanders, Belgium, connected to the Vrije Universiteit Brussel. read more
ThromboGenics NV (Euronext Brussels: THR) and BioInvent International (OMXS: BINV) announce today that they won “Licensing Deal of the Year” at the Scrip Awards 2009, presented last night. read more
Gimv and Agri Investment Fund (AIF) announced today the launch of the Gimv Agri+ Investment Fund. The new fund focuses on innovative companies in the agricultural sector and related sectors in the Benelux and neighbouring countries. Gimv Agri+ Investment Fund will start out with EUR 60 million. read more
reMYND NV (‘reMYND’) announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in early stage drug discovery. read more
Ablynx [Euronext Brussels: ABLX], announced today that it will receive an undisclosed milestone payment from Novartis. The payment has been triggered by successful delivery to Novartis of Nanobody® candidates which met specific criteria. read more
Wetenschappers van de Vrije Universiteit Brussel zijn erin geslaagd om menselijke embryonale stamcellen om te zetten in longweefsel. Deze nieuwe techniek zou in de toekomst een alternatief kunnen vormen voor longtransplantaties bij mensen met chronische longziekten of erfelijke aandoeningen zoals mucoviscidose. read more
Galapagos NV (Euronext: GLPG) announced today that it has started a Phase II clinical study to evaluate Nanocort’s effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments. read more
ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. read more
TiGenix strengthens its product portfolio and biomaterials platform through the acquisition of Orthomimetics, a privately held medical technology company based in Cambridge, the United Kingdom. This acquisition fits with TiGenix’ growth strategy of becoming a leading player in the promising and fast-growing field of regenerative medicine. read more
